TOP TEN perturbations for P21452 (Homo sapiens)

Organism: Homo sapiens
Gene: P21452
Selected probe(set): 214348_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P21452 (214348_at) across 5961 perturbations tested by GENEVESTIGATOR:

endometriosis study 5 (endo. lesion; proliferative MCP) / endometriosis study 5 (eutopic endometrium; proliferative MCP)

Relative Expression (log2-ratio):2.2553205
Number of Samples:8 / 8
Experimental endometriosis study 5 (endo. lesion; proliferative MCP)
Peritoneal endometriosis lesion samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, and the knowledge of the patient’s last menstrual cycle.
Control endometriosis study 5 (eutopic endometrium; proliferative MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.

lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):-2.170127
Number of Samples:43 / 4
Experimental lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; adenosquamous carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):2.0372
Number of Samples:4 / 22
Experimental lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted).

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-1.6225262
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

colorectal cancer study 4 (metastatic progression) / adjacent colon tissue (metastatic progression)

Relative Expression (log2-ratio):-1.3090944
Number of Samples:23 / 4
Experimental colorectal cancer study 4 (metastatic progression)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer with metastatic progression.
Control adjacent colon tissue (metastatic progression)
Histologically normal colon tissue samples from patients with primary colorectal cancer and metastatic progression collected after resection. Tissue was further extracted using laser-capture microdissection (LCM).

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):1.3074932
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

atopic dermatitis study 20 (lesional; placebo; baseline) / normal skin tissue

Relative Expression (log2-ratio):-1.253439
Number of Samples:6 / 2
Experimental atopic dermatitis study 20 (lesional; placebo; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before placebo treatment (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline.
Control normal skin tissue
Skin tissue biopsies obtained from control subjects.

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-1.180542
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

endometriosis study 5 (endo. lesion; secretory MCP) / endometriosis study 5 (eutopic endometrium; secretory MCP)

Relative Expression (log2-ratio):1.1638832
Number of Samples:10 / 9
Experimental endometriosis study 5 (endo. lesion; secretory MCP)
Peritoneal endometriosis lesion samples collected from women with endometriosis in the secretory menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, and the knowledge of the patient’s last menstrual cycle.
Control endometriosis study 5 (eutopic endometrium; secretory MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the secretory menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined based on combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.

colorectal cancer study 2 / adjacent colon tissue

Relative Expression (log2-ratio):-1.1120167
Number of Samples:32 / 23
Experimental colorectal cancer study 2
Human colon carcinoma sample.
Control adjacent colon tissue
Histologically normal colon tissue samples from patients with primary colorectal cancer.